Author: Marian Vasilescu

Slots gaming : Mega Moolah, a very good slots game

Microgaming’s most famous and highest-paying progressive has been going for ten years now and the size of the progressive jackpots being won, just keeps on increasing.

First off, let us explain a little about the Mega Moolah jackpot game and how it is actually available in more than one theme. While most people are well aware that Mega Moolah is the big progressive jackpot game, you can actually play several other slots that share the same huge jackpot fund. In this article, we are going to primarily focus on the original Wild Africa themed slot for the review, but you can attempt to win the progressive playing any of the three other themes; American, Egyptian, and Holiday theme.

Now that we understand that you can land the Mega Moolah jackpot playing more than one slot, it’s now time to explain that the Mega Moolah progressive jackpot bonus game contains not just one jackpot, but four. The jackpot bonus game is triggered randomly, however the player may increase the chances of triggering the bonus game by betting the maximum amount.

Please note that the default currency of Mega Moolah is Pound Sterling (GBP). However the game can be played world wide and in various different currencies. This means that when a jackpot is won in a currency other than GBP, say, Canadian Dollars, then the amount is paid out in CAD, not GBP. Also note that only when the jackpot is actually won in GBP does the jackpot reset to 1 million. When won in another currency the jackpot resets to a converted value. For example, if the jackpot value is GBP 10 million but it is won by a player playing in Canadian dollars, then the player has won CAD 10 million, which is around GBP 6.3 million. Therefore the jackpot would reset to around GBP 3.7 million (depending on the forex of the day).

The progressive jackpot game takes on a different form to the base game slot behind it as it is a wheel. On that reel are four different coloured sectors, each sector, depending on the colour, corresponds to one of the four Mega Moolah jackpots available. Mini, Minor, Major and Mega.

Obviously, there are more slots on the reel for the smaller jackpots and when this wheel is triggered, the wheel is spun and when the wheel comes to rest, the jackpot the selector is pointing to is the one won by the player. Most of the time players will hit the Mini or Minor Jackpots, but occasionally a Major Jackpot is won but every so often, the Mega Jackpot is triggered and somebody somewhere celebrates a guaranteed 1 million+ credit win and often far, far more than that, as can be seen on our Mega Jackpot tracker page.

You can only randomly trigger this Jackpot wheel however if you are playing the Mega Moolah base game, so now is a good time to learn a little more about this most popular of progressive slots.

The theme of the original Mega Moolah slot is an African Safari and it is a 5×3 reel slot, with 25 pay lines in operation and a maximum bet size of 125 coins. That equates to around 6.25 per spin, so you don’t have to break the bank betting large sums on every spin in order to give yourself a chance of the jackpot.

In addition to this game, there are Egyptian, Summer and Car themed variants of the slot. Mega Moolah Isis, Mega Moolah Summertime and Mega Moolah 5 Reel Drive all share the same 4 progressive jackpots with the original game. As well as the different themes, there are also differences across the other games in terms of the number of free spins that can be won, the multipliers, as well as a gamble feature in some, which does not appear in the original game. This game may have been around for a while, but it has not lost any of its appeal. The graphics are bright and colourful, and the sound effects match the wild African theme perfectly. The hope of hitting the progressive jackpot adds a lot of excitement to the game, but as with all progressives, chances of playing the bonus game are minimal. Yet luckily there are plenty of regular, smaller payouts, that enable you to keep playing and potentially boost your bank balance. Whats more, the free spins and wilds also offer the chance to multiply winnings. If you have played Mega Moolah, why not share your experiences with other players. You can use the comment form below to add your thoughts.

More @ Mega Moolah Progressive jackpot.

Have you ever asked yourself why you play slots at all? Is it maybe because you find their spinning reels relaxing, or perhaps because you enjoy their colourful visuals? For a lot of you, the answer is a lot more simple its because of the money! While poker and blackjack offer seasoned gamblers the chance to become millionaires, slots have always been there to provide the same opportunity to people who cant bluff or count cards all that well. And while most winnings on slot machines arent particularly high unless you get a bonus game or something like that, theyre not why were here no, we came for the reels, but we definitely stayed for the jackpot! The promise of a life-changing, multi-million pound jackpot has enticed people for years, and in the online space, theres really no jackpot that is more famous than the one Mega Moolah offers. Never dropping below 1,000,000, this progressive jackpot has made several people millionaires already, and for a while it also held the record for biggest jackpot won from an online slot, so draw your own conclusions!

By Gambling ,

Cryolife news

Asian’s Godfather of Cord Blood, Professor Takahashi Tsuneo Joined the “Cryolife Cord Blood Bank” and “Hong Kong Medisun”

In May 2017, CRYOLIFE Cord Blood Bank (Hong Kong Medisun Medical Group members) formally appointed the Godfather of Cord Blood in Asia, Japanese regenerative medicine expert Professor Takahashi Tsuneo as the Chief Scientist. Professor Takahashi will lead all the cord blood stem cell research projects. Professor Takahashi has eras of experience in the field of regenerative medicine. In the past few decades, Professor Takahashi has established the standards of the Cryo-Cord Blood in Asia and lead a new prospective in the application and development of the cord blood industry.

It is well believes that by the joining of Professor Takahashi will convey a new development stage in the field of cord blood stem cells in Hong Kong. It will bring new opportunities for the expansion of Medisun Medical Group and the Cryolife Cord Blood Bank.

Professor Takahashi Tsuneo is committed to the field of regenerative medicine for more than 40 years (mainly in the field of stem cells and cord blood bank). Currently he serves as Chief Executive Officer of Japan LIFEBANK and Chief Scientist of Hong Kong Cryolife Cord Blood Bank (Cryolife is a members of the Medisun Group). Prof. Takashi Tsuneo graduated from the Hokkaido University in Sapporo, Japan with a Ph.D. degree. He became the scientist in the Red Cross of Bethesda, Maryland. He later worked at the Research center for Arthritis, Diabetes and Kidney diseases of the National Institutes of Health in Bethesda, Maryland. Professor Takahashi Tsuneo returned to Japan, became the Red Cross Hokkaido Blood Center’s Research Director in Sapporo. Professor Takahashi is not only a founding member of the International Cord Blood Bank Alliance (NETCORD), but also Director of the Tokyo Cord Blood Bank Cell Treatment Center at the University of Tokyo, Japan, and Director of Cellular Research and Development for research center for cell therapy in New York. Professor Takahashi is a Visiting Professor at a number of well-known institutions, including: Department of Cellular Processing, Institute of Medical Sciences, University of Tokyo, Head of Hematology, Tokyo University Hospital, Head of Embryonic Stem Cell Research, Faculty of Forensic Medicine, Kyoto University, Kobe University Institute of Medicine and Pathology, and Department of Medicine, Peking University, China.

Application of Cord Blood

Cord blood is originated in the fetus, and collected at the umbilical cord ligation when separated from the residual placenta. Nearly a decade of research and discovered that umbilical cord blood contain the human hematopoietic and the hematopoietic stem cells of the immune system. It can be used for hematopoietic stem cell transplantation, for the treatment of more than 80 kinds of diseases. Thus, the cord blood has become an important source of hematopoietic stem cells, especially for no directly related family members. The hematopoietic stem cells is a very important human biological for treatment of diseases.

Worldwide, cord blood has been used to treat various types of Leukemia, Aplastic Anemia, Lymphoma, Multiple Myeloma, Neuroblastoma, Mucopolysaccharide disease, Thalassemia, Bone Marrow Dysplasia syndrome, Primary Immunodeficiency Disease, Chronic Granuloma and other 80 kinds of diseases.

Clinical application case

* The world’s first cord blood transplantation: In 1988, a 5-year-old French boy, suffering from Cooley’s Anemia has been treated with the cord blood transplantation and with completely recovered.
* The world’s first autologous cord blood transplantation: In 1997, a 14-month-old Brazilian girl, with autologous cord blood successfully cured Neuroblastoma.
* The world’s first double dosages of cord blood transplantation: In 2000, the Institute of Hematology of the Peking University used the world’s first double dose of cord blood transplantation for the treatment of Acute Lymphoblastic Leukemia with good result. Now, the patient weight of 95 kg, is having a healthy life.
* Asia’s first autologous cord blood transplantation: In 2009, Beijing Children’s Hospital, a pediatric patient using his own cord blood for the treatment of Neuroblastoma. This is the first case of autologous cord blood treatment for pediatric case. The baby is treated and being fine after the transplantation.
* China treated a youngest and light weight baby: In 2009, Shanghai Dao Pei Hospital has successfully treated a 2 months old baby only weight – 5 kg, by using the cord blood transplantation treatment for Primary Immunodeficiency Disease.
* In China, the first mother received the son’s cord blood transplantation as treatment: In 2009, Chongqing Xinqiao Hospital, a female patient suffering from an Acute Non-Lymphocytic Leukemia was treated by using her son’s umbilical cord blood, together with his husband’s bone marrow for transplantation. She was discharged from the Intensive Care Unit after one month from the transplantation. This is the first case of mother using her child’s cord blood for transplantation.

Treatment prospects

Cell therapy has been a biological way for the treatment of a number of diseases in the 21st century. At the end of May 2014, the worldwide of related clinical research on the cord blood cell therapy, registered with the United States National Institutes of Health (NIH) reached a total of 928.

CRYOLIFE Cord Blood Bank – Hong Kong’s first private cord blood bank

CRYOLIFE Cord Blood Bank is the only one in Hong Kong with the most international professional certification, and is highly recommended by gynecologist, physicians and parents. CRYOLIFE was established in 1996 to create the first private cord blood storage program in Asia. Prior to the establishment of the cord blood bank in Japan, Singapore, mainland China, Taiwan and Malaysia. Cryolife upgrades the standards in the development and research in the laboratory equipment. It is the leader in Hong Kong and Asian in the cord blood industry. CRYOLIFE has been recognized by the American Association of Blood Banks (AABB) since 2007 as one of the world’s first recognized AABB-approved cord blood banks, and range the first 50 in the Cord Blood Bank’s list. Continuous assessment were done in 2009, 2011, 2013 and 2015 and has successfully passed the review, and gain the AABB certification until the end of 2017. The company is the only one in Hong Kong which has obtained a 10 consecutive years’ certification in the private cord blood bank. (In February 2017) Hong Kong Medisun Medical Group acquired 51% stake in CRYOLIFE Cord Blood Bank as its controlling shareholder.)

MEDISUN MEDICAL GROUP

Headquartered in Hong Kong, Headquartered in Hong Kong, the company is committed to investing in R & D and commercialization of global regenerative medicine products, as well as professional medical investment groups in top hospitals and treatment centers.

Medisun invests extensively in regenerative medicine and stem cell patented technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, neurological diseases, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun Medical and the US Mayo Clinic, Harvard University Stem Cell Research Institute, Johns Hopkins School of Life Science Center launched a long-term cooperation program, co-investment in regenerative medicine and stem cell therapy technology. Medisun collaborates with them as the business owned holdings and holds global intellectual property rights.

The Medisun Regenerative Medical Center is located in Kowloon, Hong Kong , with 50,000 square feet of stem cell GMP production base, cancer treatment center and anti-aging center, bringing together European, Japanese, American and individual Chinese experts for rigorous professional development process by providing immune cell therapy and a variety of stem cell treatments. Medisun is also the Asian Center, a representative of the Mayo Clinic Asia service agencies. It provides Mayo remote consultation, the second diagnosis and treatment, so that Chinese patients can not enjoy the authority of the medical services. Mayo Clinic provides more than three thousand biomedical tests for the most predictable health protection for our customers’ health.

Medisun Regenerative Medicine Center (Mayo Asia Medical Service Center | Cancer Treatment Center | Anti-Aging Center)

Medisun Medical Laboratory (Hong Kong)

Source : http://www.medisun.hk/

By Health

Mig Welder Ireland

Looking for plasma cutter for a project in Ireland? You can check this complete welding solutions online store at Migwelders.ie.

Oxford Welder provider Ireland : MIG Welders are extremely popular because they tend to cost less than TIG or Stick welders with comparable power and features, are extremely easy to learn, and can tackle a wide variety of projects. Since the filler metal is fed through the MIG welding torch, welders can use both hands to hold the torch steady rather than using one hand to add filler metal, as in TIG welding. The wire feeder also makes MIG welding up to four times faster.

The MIG welding process uses an inert gas to shield the weld and to keep it free from impurities. This makes MIG welding very neat and easy to clean up since there isn’t anything to chip away, which is typical for Stick welding.

Some tips on choosing the best welding equipment and also some industry news:

Weight of machine Do you require a machine that needs to be moved around and transported to jobs, or will it remain within a workshop?

Take into account the duty cycle of the machine!! You may need 160amps and a machine may state that it does this, but it could only be at 15% duty cycle, which means it could only weld at 160amps for 1.5mins out of every 10mins? Unless you are only do very short welds its best to work on a 35% duty cycle when choosing your machine.

Where the machine is manufactured and are replacement parts available in your country? Time and time again we have customers who cannot get spares for their machine when it breaks down. MigWelder.Ie has all the spare parts for all the machines on the shop.

Purchasing a welder is an important long term decision that can add extra income to your bottom line, save on repair costs, and make it possible to complete a wide array of hobbies. The options can be overwhelming, and that is why we’ve put together this welder buying guide. You’ll find important details to consider, a comparison of welder types, and information about the top selling brands from Baker’s Gas and Welding.

One of the most important questions to consider when selecting a welder isn’t what projects it will be used for in the next week, month, or even year. Those interested in buying a welder need to ask if they see themselves using it more frequently in the future for many different kinds of projects.

TWS Direct Ltd. Unit 1 M54 Space Centre.
Halesfield 8. Telford. Shropshire. TF7 4QN
Phone :
+44 (0) 1952 582 260
Website: https://www.migwelders.ie/
Email :sales@weldingsuppliesdirect.co.uk; MIGWELDERS.IE are a welding equipment and welding consumables supplier based in Shropshire, UK. We strive to provide the best MIG welders, TIG welders and welding consumables in Ireland. We are the home of Oxford welders in Ireland, with plenty of machines carried in stock for fast delivery!

By Shopping , , ,

The famous american virologist Robert Gallo joined Medisun Medical Group

The famous American virologist – HIV virus discoverer Robert Gallo joined Medisun Medical Groupedisun

Bringing the best cancer and AIDS treatment technologies to China

Robert Gallo, a famous American virologist, joined Medisun Medical Groupedisun

In February 2017, Medisun Medical Group officially announced the appointment of Robert Charles Gallo, a famous American virologist, as a member of the board of directors of the group.

https://pbs.twimg.com/profile_images/461587078824738817/w8khfwWL.jpeg 

Dr. Robert Charles Gallo

Dr. Gallo is a famous American virologist whose best-known contribution is the discovery of the first human retrovirus (HTLV1, and HTLV2). In 1983, HTLV3 was discovered, which was later called the HIV, a virus that causes AIDS. He also studied the cytokine leukocyte 2, and in 1986 studied the pathogen human rash type 6 virus in children with acute rash. In 1982 and 1984, he received the Lasker Basic Medical Research Award (known as the “Nobel Prize in the United States”), the Charles Mott Award (Tumor Prevention Contribution Award) in 1984, and the Dickson International Award in 1985, 1988. Received the National Science and Technology Outstanding Contribution Award from Japan. Dr. Gallo is currently the Director of the Institute of Human Virology (IHV) at the University of Maryland and the founder and chief scientist of the Global Virus Network (GVN). He has served in the National Cancer of the United States. The National Cancer Institute has served as the director of the Laboratory of Cancer Cell Biology for 30 years. Dr. Gallo proposed the theory that the tumor system is caused by viruses and gradually improved its academic structure and clinical research.

Mr. Terry L. Lierman, founder of the US FDA, joined Medisun

At the same time , Mr.Terry L. Lierman entered the board of Medisun. Mr. Lierman is the founder of Summit Global Ventures and the CEO of Health Ventures LLC.Mr. Lierman has served on the US Senate Appropriations Committee and served as Director of the Sub-Committee on Labor Health and Human Services (HHS) Grants. Mr. Lierman is also the founder of Research America and NIH (National Institutes of Health) / FDA (US Food and Drug Administration) Board of Directors, and serves as the majority leader and member of the House of Representatives. He began his career in the health field of the NIH (National Institutes of Health) in 1971, where he assisted with budget and policy development, grants and contracts. For the past four decades, he has combined entrepreneurs and political talent in a variety of businesses.From leadership positions in the US Senate Appropriations Committee, founding companies and non-profit organizations, to promote health care advocacy, to lead and serve as chairman of the Maryland Democratic Party.

Mr.Terry L.Lierman

Chairman Medisun Wang Xiaofeng joined the Board of Directors of the Institute of Human Virology and the International Virus Alliance

At the same time that two world-class companies joined Medisun, Mr. Wang Xiaofeng, Chairman of Medisun Medical Group, was also invited to the Institute of Human Virology (IHV) and the Global Virus Network (GVN) at the University of Maryland as a member of the board of directors. Mr. Wang is the founder and chairman of the Board of Directors of Medisun Medical Group living in Canada and the United States for ten years. He moved to Hong Kong in 1996. Mr. Wang has more than 20 years of experience in the global capital market and medical industry, including industries including Medisunne, internet, education and media. Mr. Wang is currently Chairman of Hong Kong-listed National Investment Fund (01227.HK) and Chairman of Beijing Financial Group.

Mr. Danny Wong

Headquartered in Hong Kong, Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative Medisunne products, as well as top hospitals and treatment centers.

Medisun invests extensively in the fields of regenerative Medisunne and stem cell patent technology, including stem cell therapy for heart failure, stem cell therapy for liver disease, kidney disease, nervous system disease, cancer, AIDS, and immune cell therapy for a variety of cancers. Medisun Medical has a long-term cooperation plan with the US-Australia Clinic, the Harvard University Stem Cell Institute, and the Johns Hopkins Medical School Life Science Center to jointly invest in regenerative Medisunne and stem cell therapy technology, with Medisun as a co-operative business. The Medisun holding entity and holds global intellectual property rights.

The Medisun Reproductive Medisunne Centre is located at the Proud Square in Kowloon Bay, Hong Kong. It has a 50,000 square foot stem cell GMP production base, a cancer treatment centre and an anti-aging centre. It brings together European, Japanese, American and individual Chinese experts to develop a rigorous and professional R&D process. Provides immune cell therapy and a variety of stem cell health treatments. As the Asian service organization of Mayo Clinic, the center provides Mayo remote consultation and secondary treatment to enable Chinese patients to enjoy authoritative medical services without leaving the country. 3,300 biomedical tests provide the most predictable health protection for customers’ health, adding more than 300 new testing items each year.

MEDISUN REGENERATIVE MEDICAL CENTER | CANCER TREATMENT CENTER | ANTI-AGING CENTER

Medisun Medical Laboratory (Hong Kong)

Medisun Medical Laboratory (Hong Kong)

Medisun announced that he will join the Biden Cancer Lunar Plan

At the end of 2016, Medisun announced that he would join the “Cancer Moon Plan” initiated by former US Vice President Biden. The “Cancer Moon Plan” was proposed by former US President Obama in early 2016 and was initiated by former Vice President Biden. The goal is to shorten the work schedule for cancer-related prevention, diagnosis, treatment and care that was expected to be completed in 5 years. Aiming to achieve 20,000 cancer treatments worldwide by 60 programs by 2020.
Dr. Gallo and Mr. Lierman will lead Medisun’s clinical research implementation, medical technology and project selection, medical resource introduction, etc., and bring the best technology in the world to China, highlighting the inevitable trend of China’s participation in the world’s most advanced technology research and development. . At the same time, Medisun’s clinical research bases in Hong Kong, Beijing, Shanghai, Guangzhou and Tokyo will participate in the world’s most advanced clinical research.
Dr. Gallo and Mr. Lierman joined Medisun and Chairman Wang Xiaofeng to enter the IHV and GVN Board of Directors, indicating that Medisun will work with IHV and GVN to make valuable preparations for the cancer landing program and to fully participate in the global research and development of cancer treatment.

The Human Virology Institute (IHV) is the world’s first research center that combines basic science, epidemiology and clinical research disciplines to accelerate the diagnosis and treatment of chronic viruses and immune diseases (mostly HIV, AIDS the reason). IHV’s laboratory is a US key laboratory that receives more than $200 million in annual US research funding.
Founded in 1996 as a partner of the University of Maryland, IHV is a research institute at the University of Maryland School of Medisun, bringing together a globally recognized and world-renowned expert in human virology. The IHV was co-founded by Robert Gallo (Director of IHV) and William Blattner.MD. The IHV also includes the Animal Model Department, the Basic Science Department and the Vaccine Research Department.
The institute has a variety of laboratory and patient care facilities located in Baltimore, Maryland. IHV has created an environment of close collaboration between multidisciplinary research, education and clinical research and development, accelerating scientific understanding of the incidence of HIV/AIDS, and developing interventions to curing cancers of HIV and viruses possible.
IHV’s research focuses on how to use the body’s natural chemistry to its own therapeutic potential, and to discover biotherapeutics that are less toxic to the body and more economical for the public. IHV is also committed to developing effective therapeutic and preventive vaccines that are dedicated to ending the AIDS epidemic.
IHV has more than 300 employees, including 70 professors, whose research focuses on chronic human viral infections and diseases. Currently, more than 75% of the Institute’s clinical and research work addresses HIV infection, but also includes hepatitis C virus, human T-cell leukemia virus 1 and 2, human papillomavirus, herpes virus and cancer research. The patient base of IHV has grown from just 200 patients to about 6,000 in Baltimore, and nearly 1 million in 6 African and 1 Caribbean countries.

The Global Network of Viruses (GVN) is a global organization for the research of viral diseases. It is a consortium of authoritative virologists from more than 20 countries around the world. It is dedicated to the research, development of drugs and vaccines to prevent diseases and death. GVN is the only single organization in the world that has special research in all areas of the virus. GVN brings together the world’s best medical virology experts to focus on difficult scientific issues around the world. The strength of GVN lies in its global reach, the depth of science, and its vision to address the viral challenges facing humanity.

GVN achieves its goals through three strategic action platforms:

Support research

Public education

Advocate a statement supporting the global virus network

Established in Washington, DC, the organization supports the goals and ideals of a global virus network, actively trains younger generations of medical virologists, and provides advice to governments or NGOs on viral diseases to fill the current international health development important needs.

Source: http://www.medisun.hk/

By Health

GreenSpace Brands Announces Acquisition of US Based Galaxy Nutritional Foods, Owners of the Go Veggie Brand

GreenSpace Brands Inc. (“GreenSpace”) (TSXV: JTR) is pleased to announce today that it has signed a share purchase agreement dated December 20, 2017 to acquire (the “Acquisition”) all of the outstanding shares of Galaxy Nutritional Foods Inc. (“Go Veggie”), which owns the Go Veggie? brand. Go Veggie is one of the leading cheese alternative brands in the United States with distribution in over 12,000 locations through most major US grocery retailers and natural food chains, along with a growing food service business. The plant based dairy alternative market is one of the fastest growing subsets of the natural food market, but has very few established players. Go Veggie has established itself as one of the preeminent brands in the space with some of the best tasting and award winning products.

Greenspace will be holding a conference call to discuss the details of the transaction on December 21st, 2017 at 9:00 EST. The call will be hosted by Matthew von Teichman, President and Chief Executive Officer. Following management’s presentation, there will be a question and answer session for analysts and investors. To participate in the teleconference, dial (647) 427-7450 or 1 (888) 231-8191 (Toll-free). Callers are advised to call five minutes in advance of the call.

A taped rebroadcast will be available beginning at 11:20 am (EST) December 21st, 2017 until 11:59 pm (EST) on December 28th, 2017. To access the rebroadcast, please dial (416) 849-0833 or 1 (855) 859- 2056 and use the passcode 1289656 followed by the number sign.

Overview of the Acquisition

GreenSpace has agreed to purchase Go Veggie for a total consideration of $17.8 million USD, comprised of $4.5 million USD in cash, $7.62 million USD (approximately $9.81million CAD) in GreenSpace common shares (the “Share Consideration”), and a two year vendor take back loan of $5.72 million USD, carrying an 8.5% coupon. Greenspace will issue 7.16 million Common shares at $1.37 per share as part of the transaction, a 14.2% premium to the closing market price on December 19th, 2017.

GreenSpace will be purchasing Go Veggie from Mill Road Capital, a Greenwich, Connecticut based private investment firm focused on investing in and partnering with publicly traded micro-cap companies. Mill Road will become the largest shareholder of GreenSpace as a result of this transaction. Mill Road Capital has a long history of successfully investing in emerging consumer brands throughout Canada and the United States, and this expertise will help support the GreenSpace team as they navigate the US natural food market and US capital markets.

The Share Consideration will be subject to lock-up and escrow pursuant to which approximately 45% of the Share Consideration shall be locked up for 12 months from the closing date, 5% of the Share Consideration shall be in escrow for 13 months from the closing date and the remaining 50% shall be locked-up for 18 months from the closing date, subject to certain exemptions.

Select highlights of the Acquisition include the following:

Go Veggie adds a profitable pre-existing US platform that will enable GreenSpace to launch its most innovative and unique brands into the US;

The acquisition is expected to add significant gross margin dollars to GreenSpace and improve the overall gross margin profile, as well as add incremental adjusted EBITDA in the short term, with more significant growth in adjusted EBITDA over the long term. Go Veggie recorded revenues of $16.3 million USD for their fiscal year ended March, 31, 2017, with strong gross profit margins of approximately 40%.1
Go Veggie has one of the leading brands in what GreenSpace believes to be one of the fastest growing segments of the natural food industry, plant based dairy alternatives. Galaxy has broad based distribution across the United States and an existing high functioning team; and

GreenSpace believes that by supporting updates and amplifying the brand image of Go Veggie, it will be able to further develop its leadership position in the plant based dairy alternatives vertical in North America;

“We couldn’t be more excited to add Go Veggie to the GSB family of brands. With the acquisition of Go Veggie, we enter our most sought after vertical, plant based dairy alternatives. The addition of Go Veggie adds a profitable pre-existing US platform that will enable us to launch our most innovative and unique brands into the US under the expert leadership of one of the most respected people in the US natural food industry, Rick Antonelli, CEO of Go Veggie” comments Matthew von Teichman, CEO of Greenspace, “This is truly a transformative acquisition for us. We will continue to develop their Canadian sales strategy through the leveraging of our current platform and strategically initiate our US development by leveraging their platform. It’s a win-win and the ideal way for us to get going in the US market”

Rick Antonelli, CEO of Galaxy comments, “We’ve been watching GreenSpace for years and have admired the stable of brands they’ve been able to put together in such a short time. We feel that Go Veggie is a perfect addition to that roster of strong brands and with the potential synergies of our team selling their products, and their team selling our products, there’s a significant long term upside for both. I can’t wait to start presenting GreenSpace’s unique and innovative products to the US market and Go Veggie’s existing retail partners.”

The Acquisition is scheduled to close in January 2018, subject to satisfaction of customary closing conditions and approval of the TSX Venture Exchange. Financo, Inc. has acted as the exclusive advisor to Galaxy and Mill Road.

About GreenSpace

GreenSpace is a Canadian-based brand ideation team that develops, markets and sells premium natural food products to consumers across Canada. Greenspace owns and operates the following brands: Love Child Organics., one of the fastest growing brands in Canada and a producer of 100% organic food for infants and toddlers made with the pure, natural and most nutritionally-rich ingredients; Central Roast, a clean snacking brand that has been one of the leading natural food brands in Canada; Rolling Meadow Dairy, Canada’s leading grass fed dairy product line, delivering premium fluid and cultured products across Canada; Life Choices which features premium convenience meat products made with grass fed and pasture raised meats without the use of added hormones and antibiotics; Kiju, the Canadian market leader in the shelf stable organic juice segment; Cedar , the Canadian leader in cold pressed and gut health fresh juices. All brands are wholly owned and retail in a variety of natural and mass retail grocery locations across Canada.

GreenSpace’s filings are also available at www.SEDAR.com

About GO VEGGIE?

Over 40 years ago Galaxy Nutritional Foods Inc. created the cheese alternative category for health-conscious consumers and is proud to remain America’s leading provider of great tasting cheese-free products. Today, under Galaxy’s new brand GO VEGGIE, the company continues to innovate and offer consumers more healthy cheese-free choices. Across its product portfolio – Vegan, Lactose Free, and Lactose & Soy Free – GO VEGGIE offers 55 products across the United States in a wide variety of formats.

For product information, recipes, and more, visit www.goveggiefoods.com. Follow GO VEGGIE on Facebook, Twitter, Instagram, and Pinterest.

About Mill Road Capital

Mill Road Capital is a private investment firm focused on investing in and partnering with publicly traded micro-cap companies in the U.S. and Canada. The firm has flexible, long-term capital with the ability to purchase shares in the open market, buy large block positions from existing shareholders, provide capital for growth or acquisition opportunities, or execute going-private transactions. The firm has raised approximately $670 million of aggregate equity capital commitments and has offices in Greenwich, CT and the San Francisco Bay Area. Mill Road’s investments in Canada include Ten Peaks Coffee Company, a British Colombia based premium green coffee decaffeinator, PRT Growing Services Ltd., the British Columbia based leader in container grown tree seedlings for replanting forests, and Cossette, the largest full service advertising agency in Canada.

More information can be found at http://www.millroadcapital.com.

Forward Looking Information

Certain statements in this press release may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, statements concerning (i) the Acquisition; (ii) the completion of the Acquisition; (iii) anticipated approvals; (iv) the time to the closings; and (v) results of the completion of the Acquisition. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “outlook”, “objective”, “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “should”, “plans” or “continue”, or similar expressions suggesting future outcomes or events. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by such statements. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including, without limitation, the risks that: (1) the information provided to GreenSpace by Galaxy turns out to be misleading, untrue or incomplete; (2) the Acquisition may not be completed for any reason whatsoever, including that regulators may not approve the Acquisition; (3) the closings may not occur as scheduled or at all; and (4) GreenSpace may not achieve the results currently anticipated. Although GreenSpace believes that the expectations reflected in its forward-looking information are reasonable, undue reliance should not be placed on forward-looking information because GreenSpace can give no assurance that such expectations will prove to be correct. In addition to other factors and assumptions which may be identified in this press release, assumptions have been made regarding and are implicit in, among other things, the timely receipt of required regulatory approvals. Details of the risk factors relating to GreenSpace and its business are discussed under the heading “Risk Factors” in the preliminary short form prospectus filed on the date hereof and “Risks and Uncertainties Related to the Business” in GreenSpace’ annual information form dated July 18, 2017, a copy of which is available on GreenSpace’ SEDAR profile at www.sedar.com. Readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which have been used. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks and uncertainties which could cause actual results to differ materially from those anticipated by GreenSpace and described in the forward looking information. The forward-looking information contained in this press release is made as of the date hereof and GreenSpace undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless required by applicable securities laws. The forward looking information contained in this press release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release does not constitute or form a part of any offer or solicitation to buy or sell any securities in the United States or any other jurisdiction.

By Food , , ,

Hire full stack developer and technology leaders

How to become a full stack developer? As one of the hottest topics for developers, the discussions have never stopped. On LinkedIn and Facebook, lots of people put their job title as a full stack developer. Besides, it seems that the Full Stack topic has already become a new job trend. An article on Medium has discussed the full stack designer getting both praise and blame. Some people think that the full stack is just a title, what he/she should focus on is the real personal ability and technology.

Essentially, I think the discussion about the full stack is also a kind of argument relating to the all-rounder and expert in the IT industry, and debate on the depth and breadth of development skills.

You cant have your cake and eat it too. While the full stack developers and full stack designers seem like they are challenging this possibility. Because their horizontal skills tree gives them the ability to both have and eat the cake. There is another saying is that jack of all trades, but master of none. So its necessary to think about how to become a real full stack developer but not an empty title.

So by definition a developer who works on front-end is a front-end developer and a developer who works on back-end is a back-end developer.

Front-end developers are responsible for a websites user-interface and the user-experience architecture. They work closely with designers to construct and improve the ui/ ux of a website. A good front-end developer can be able to accurately identify specific issues in user-experience and provide recommendations and coding solutions to improve the design.

Almost every single program, whether online or in-person, that is teaching you how to be a web developer will start with HTML and CSS because they are the building blocks of the web. Simply put, HTML allows you to add content to a website and CSS is what allows you to style your content. The following topics related to HTML/CSS come up often in interviews and on the actual job when youre working:

Semantic HTML.
Be able to explain the CSS Box Model.
Benefits of CSS preprocessors (you dont necessarily need to understand how to use one on a deep level, but you should to understand what they are for and how they help with development).
CSS Media Queries to target different devices and write responsive CSS.
Bootstrap (a framework for helping design and layout content on a page and while many online programs or schools focus heavily on teaching Bootstrap, in reality its more important to have a deep knowledge of fundamental CSS than specific Bootstrap features and methods).

full stack web development – LeewayHertz has given 360-degree solutions to the enterprise and fortune 500 companies with their full stack development. Their full stack developers are technology researchers and leaders. LeewayHertz holds the capability to drive the thinking digitally along with the Full Stack Web implementation.

Keeping our UI/UX strategies, innovative web designs and the agile workflow, our designs have been rated as the most converting and engaging among top technology partners. LeewayHertz delivers the high-quality UI/UX designs for every development cycle.

During out DevOps Agile Cycle, the Testing Team picks up the Jira Issues to conduct the scrum daily. After the resolution of issues, the Code Repo triggers the commit code into the Jenkins in three states, i.e., Jenkins QA, Jenkins UAT, Jenkins Prod. Once the code is committed, Hockeyapp and the AWS continuously delivers the build for testing through the provisionary tools.

By Software , ,

Sell My House Fast In Atlanta Vine City

If you want to sell your house fast in Atlanta were buying homes cash. We specialize in buying houses fast. Are you wondering How to sell a house fast. Selling your house as is? We specialize in quick sales, and we can show you how to sell your house fast, even if it doesnt fit our buying criteria. We pay cash for homes, regardless of condition.

Our first offer is our real offer! We prepare a HONEST, all cash offer based on sales in the area and market rates. Most cash buyers will start with a low-ball offer just to see if you bite. We respect you enough to not insult your intelligence with bogus offers. We will attempt to help you sell the house with a professional edge, even if you decide not to sell to us.

We have been in business for seven years. Many times cash buyers are novice who are trying to make money doing quick fix and flips. We are sophisticated real estate professionals which means we can pay you more because we dont have to account for amatuer mistakes.

And as a bonus

– YOU DO NOT NEED TO CLEAN OR FIX THE PROPERTY, WE WILL HANDLE ALL REPAIRS.
– WE WILL HANDLE TITLE ISSUES, AND LET YOU KNOW IF THERE IS A PREVIOUS BALANCE REQUIRED TO CLOSE.
– YOU WONT BE LOCKED INTO A BINDING CONTRACT, OR DEAL WITH PAPERWORK WAITING AND WONDERING.
– YOU WONT HAVE TO WORRY ABOUT CLOSING COST, WE PAY ALL FEES.

Well know very quickly if we can help you, and unlike selling through an agent, you dont have to wait to see if the buyer can get financing were ready to buy right now!All that hassle can add stress, months to the process, and in the end after paying the agents expensive fees, you may or may not be ahead of the game. We are different at ATLFairOffer, when you contact us and submit the short property information form (below), well give you a fair all-cash offer on your house within 24 hours and the best part is: we can close whenever YOU choose to close its entirely up to you. It doesnt matter what condition the house is in, or even if there are tenants in there that you cant get rid of dont worry about it. Well take care of it for you. And if you need the cash quickly, we can close in as little as 7 days because we buy houses with cash and dont have to rely on traditional bank financing. (Go here to learn about our process : Ugly houses Atlanta Grove Park)

What Do You Have To Lose? Get Started Now…

We buy houses in ANY CONDITION in Georgia. There are no commissions or fees and no obligation whatsoever. Start below by giving us a bit of information about your property or call (404) 800 -1744

Or Give Us A Call Now At: (404) 800-1744

ATLFairOffer
400 West Peachtree St. NW Ste #4 – 622 Atlanta, GA 30308
Contact Number (404) 800-1744
https://www.atlfairoffer.com/

By Real Estate ,

Hong Kong National Investment and Harvard University Stem Cell Institute starting a strong cooperation

Hong Kong National Investment and Harvard University Stem Cell Institute have a strong cooperation.

Mr. Brock Reeve, CEO of Harvard Stem Cell Research Institute, is the Chief Investment Officer of Stem Cell and Regenerative Medisun at National Investment and Medici Medical Group.

2015-05-11 China Securities Journal

On May 8, 2015, Hong Kong Medisun Regerative Medical Center and National Investment (01227.HK) announced the appointment of Mr. Brock Reeve as the chief stem cell and regenerative medicine investment officer of the two companies.

Mr. Brock Reeve is currently the Executive Director of the Harvard University Stem Cell Institute and has graduated from Yale University and Harvard Business School. Mr. Reeve is solely responsible for the strategy and operations of the Harvard Stem Cell Institute, whose overall goal is to use stem cell biology as a tool and treatment to study and treat major degenerative diseases.

As the Chief Investor of Stem Cell and Regenerative Medicine of Medisun Medical Center, Mr. Brock Reeve will organize and lead a professional investment team to actively select the latest regenerative medicine technologies in overseas markets such as Europe, the United States, and Japan and evaluate their investment value. They will also focus on and invest in the world’s leading stem cell regenerative medicine technology, and actively participate in clinical trials and product commercialization of stem cell technology invested by Medisun Medical Center in Asia.

Medisun Medical Center is the world’s most authoritative investment organization in stem cell and regenerative medicine

As the world’s most authoritative investment organization for stem cells and regenerative medicine, Medisun Medical Center has invested in stem cell treatment technologies including heart, tumor, liver, kidney, AIDS and other diseases, fully demonstrating its investment vision and courage. After working with the Mayo Medical Group in the United States, the Medisun once again joined forces with the Harvard University Stem Cell Institute.

Mr. Danny Wong is both the Chairman of the Medisun Medical Group and National Investment (01227.HK). He has devoted himself to research and investment in the field of stem cells for the past five years. The Medisun currently has more than 300 scientists , medical consultants and investment experts from all over the world. The technologies invested by the group are distributed in Europe, the United States, Japan, Hong Kong and other places, and clinical trials are carried out simultaneously.

China’s first participation in international multi-center global synchronized clinical trials

Medisun Medical Group is committed to bringing the world’s leading stem cell and regenerative medicine technologies to China. The investment in the C-cure stem cell therapy for ischemic heart failure technology, which was invented by Mayo Medical Group, has been clinically tested in Europe and the United States. It will carry out clinical trials in China’s well-known cardiovascular hospitals such as Beijing Anzhen Hospital, Fuwai Cardiovascular Hospital and Shanghai Oriental Hospital with the support of international multi-center policy, giving Chinese hospitals the opportunity to participate in the world’s most advanced stem cell technology clinic. The Medisun also actively promote the commercialization of technology worldwide in the future. Before C-Cure’s great technology and revolutionary products for heart disease were officially launched, Medisun has launched a series of cell regeneration factor products to treat a number of diseases, and the product has entered the market.

Liang Zhen ying visits Harvard University Stem Cell Research Institute and Mr. Brock Reeve to discuss the promotion of stem cell and the development of regenerative medicine industry

Under the general environment of Hong Kong’s adjustment of the whole industry, one of the important measures is to develop the stem cell and regenerative medicine industries. Looking at the huge investment in the stem cell and regeneration field of the Medisun Medical Group, it is revealed that it will inevitably set off a disruptive business model in the market.

The Hong Kong government attaches great importance to the development of stem cells. Following the cooperation with the Caroline Medical School in Sweden, Liang Zhen ying visited the Harvard University Stem Cell Research Institute on May 5 and exchanged views with its Executive Director Brock Reeve to promote the development of the stem cell industry in Hong Kong. This will undoubtedly inject a strong shot into the cooperation between Harvard University and Hong Kong in the field of regenerative medicine. It will promote the promotion of Harvard stem cells in regenerative medicine research and technology in Hong Kong and Asia.

It can be seen that Medisun Medical Group has appointed Mr. Brock Reeve take the helm of the stem cell and regenerative medicine to investment. National Investment (01227.HK), which holds a 30% stake in Medisun Medical Group, is investing in regenerative medicine and the field of stem cells. Mr. Brock Reeve will lead the Medisun Medical Group to become a professional stem cell investment team with global leadership.

The value of the stem cell and regenerative medicine industry under the capital market in China and Hong Kong is immeasurable.

With the upcoming clinical management of stem cells, the development of China’s stem cell and regenerative medicine industry will be unstoppable. Shanghai-Hong Kong Stock Connect and the upcoming Shenzhen-Hong Kong Stock Connect have apparently injected huge sums of money into Hong Kong stocks. The stocks of companies related to the stem cell industry have risen very well, but they are far from satisfactory and far from the technology held by Medisun Medical Center. National Investment (01227.HK), as a shareholder of Medisun Medical Group, is full of confidence in the development of the Group.

Medisun Investment Holdings’ Cardio Biotech plans to enter the US capital market.

Medisun Investment Holdings’ C-cure Stem Cell Therapy for Ischemic Heart Failure has exceeded the number of patients enrolled by the European Food and Drug Administration (EMA) in the Phase III clinical trial in Europe and has been approved by the US Food and Drug Administration (FDA). Enter the third phase of clinical. Cardio, the investment holding company of Medisun, also successfully obtained a new round of financing of 32 million euros in February this year. Its financing quota was oversubscribed and snapped up by European and American institutional investors. Cardio is planning to be listed on the NASDAQ in the United States from the end of May to the beginning of June this year (listed in Belgium and France in 2013), and the large-scale financing plan of Cardio further indicates that the spring of stem cells has really come.

After many years of favor and investment in the field of stem cells and regenerative medicine, and the huge capital investment plan, the Medisun’ next step will be the focus of the market. The capital market’s confidence in its shareholder, National Investment (01227.HK), is already evident in the expectation of its future development.According to analysts, Medisun has planned to launch an overall listing financing plan in Hong Kong in the near future. We believe that Medisun, as a recognized leader in the global stem cell and regenerative medicine field, will surely launch an incredible wave of development in this field.

The News Picture:

P1:

Mr. Brock Reeve is both the chairman of Medisun medical group and National Investment (01227.HK) and a close friend of Mr. Danny Wong during his stay in the United States.They share the same confidence and enthusiasm for stem cell and regenerative medicine.

P2:

Hong Kong Chief Executive Liang Zhen ying visited the Harvard University Stem Cell Institute and exchanged views with the Executive Director, Mr. Brock Reeve, on the development of the stem cell and regenerative medicine industries.

Source: http://www.medisun.hk/

Brock Reeve is the younger brother of the famous American actor Christopher Reeve. Christopher Reeve (September 25, 1952 – October 10, 2004), a New Yorker, famous movie actor, film director, writer, was play in Superman (Kal-El/Clark Kent). He graduated from Cornell University in 1974 with a Bachelor of Arts degree and then entered the Juilliard School in New York. He is also a good friend with another famous actor Robin Williams. In 1978, he starred in the sci-fi film “Superman” for the first time and became a hit. In 1995, an accident occurred during an equestrian competition. The spine was seriously injured and his body was paralyzed. Since then, he has devoted himself to social welfare undertakings and to promote stem cell research. He often holds tour lectures. On October 9, 2004, he died for the myocardial infarction at the age of 52.

By Health